US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Renaissance Technologies Holdings

1,861.23

+35.271.93%

Number of Gainers:76

Number of Losers:20

Number of Flat:- -

PE:- -

High:1,865.95

Open:1,832.50

Low:1,832.50

Close:1,825.96

Loading ...

5 Things to Know Before the Stock Market Opens

Icotrokinra Meets Primary Endpoint of Clinical Response in Ulcerative Colitis Study and Shows Potential to Transform the Treatment Paradigm for Patients

THOMSON REUTERS

J&J: Icotrokinra Was Well Tolerated

THOMSON REUTERS

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

US STOCKS-Futures decline as tariff concerns persist; Tesla falls

Novo Nordisk's CagriSema Meets Primary Endpoint in Phase 3 Trial

MT Newswires Live

Nio Making Organizational Changes To Focus More On Cost Control, Report Says

Incyte (INCY) Receives a Hold from Stifel Nicolaus

Novo Nordisk down 6% after results for trial of weight-loss drug CagriSema

Returns On Capital At Hello Group (NASDAQ:MOMO) Have Hit The Brakes

Simply Wall St.

ServiceNow Close To Buying AI Startup Moveworks In $3 Billion Deal

Egg prices have become a symbol of our economic fragility

Can EL Stock Bounce Back in Fiscal 2025 Amid Challenges?

Jazz Pharmaceuticals Plc : H.c. Wainwright Raises Target Price to $217 From $200

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4532/news?page=28"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4532"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4532\",,,,,undefined,":{"symbol":"BK4532","market":"US","secType":"PLATE","nameCN":"Renaissance Technologies Holdings","latestPrice":1861.2279,"timestamp":1741968224028,"preClose":1825.9556,"halted":0,"volume":440023569,"delay":0,"changeRate":0.019317,"change":35.272339,"pbRate":8.368157,"amount":46638426732.36167,"amplitude":0.018321,"prevYearClose":2026.1482,"fiveDayClose":1912.7213,"twentyDayClose":2056.6948,"turnoverRate":0.003419,"marketCap":20754367395632,"floatMarketCap":19422253699512,"peRate":30.56397},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4532\",,,,,undefined,":{"symbol":"BK4532","high":1865.9525,"amplitude":0.018321,"preClose":1825.9556,"low":1832.4988,"pbRate":"8.368157","latestPrice":1861.2279,"volume":440023569,"delay":0,"open":1832.4988,"prevYearClose":2026.1482,"prevWeekClose":1912.7213,"prevMonthClose":1965.7411,"prevQuarterClose":2026.1482,"fiveDayClose":1912.7213,"twentyDayClose":2056.6948,"sixtyDayClose":2078.8435,"secType":"PLATE","market":"US","turnoverRate":0.003419,"peRate":30.56397,"marketCap":20754367395632,"floatMarketCap":19422253699512,"timestamp":1741968224028,"nameCN":"Renaissance Technologies Holdings"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4532\",,,,undefined,":{"bkCode":"BK4532","up":76,"down":20,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4532\",pageSize:16,pageCount:28,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518226113","title":"5 Things to Know Before the Stock Market Opens","url":"https://stock-news.laohu8.com/highlight/detail?id=2518226113","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518226113?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:00","pubTimestamp":1741608046,"startTime":"0","endTime":"0","summary":"U.S. stock futures point lower after a volatile week of trading and President Donald Trump's comments from a weekend interview in which he failed to rule out a recession; Oracle  shares are declining ahead of the cloud services giant's third-quarter earnings after the bell; Redfin  shares soar 75% on news the digital real estate brokerage is being acquired by Rocket Companies  for $1.75 billion of equity value; and U.S.-listed shares of Novo Nordisk  are falling after the latest trial results of its CagriSema weight-loss drug. Here's what investors need to know today.Redfin  shares are jumping 75% on news the digital real estate brokerage is being acquired by Rocket Companies  for $1.75 billion. Rocket shares are sinking 11% after the Detroit-based mortgage lender said it was buying Redfin in an all-stock transaction for $12.50 per share. \"Together, we will improve the experience by connecting traditionally disparate steps of the search and financing process with leading technology tha","market":"hk","thumbnail":"https://www.investopedia.com/thmb/n-SyAfYIP_mfcNDBCjSbdp2dNeU=/800x533/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2202870636-a9d6af654d94457dac5eee63cd2d0d4c.jpg","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/n-SyAfYIP_mfcNDBCjSbdp2dNeU=/800x533/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2202870636-a9d6af654d94457dac5eee63cd2d0d4c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-march-10-2025-11693783","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["LU0320765489.SGD","LU1201861249.SGD","LU0256863811.USD","LU1935042488.USD","LU0965509101.SGD","LU1035773651.USD","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","NVO.AU","RKT.AU","LU0719512351.SGD","BK4543","LU0234570918.USD","LU1935042991.SGD","LU1366333091.USD","LU1815336760.USD","IE00BBT3K403.USD","LU0957808578.USD","NVO","LU0444973449.USD","LU0068578508.USD","BK7084","BK4548","LU0433182093.SGD","BK4538","BK4195","LU0056508442.USD","LU2236285917.USD","RDFN","LU0648001328.SGD","LU0861579265.USD","LU0878866978.SGD","LU0965509010.AUD","ORCL","LU2054465674.USD","BK4229","LU1429558221.USD","LU1934455863.HKD","BK4588","BK4532","LU0154236417.USD","LU1934455194.USD","RKT","IE0002270589.USD","IE00B19Z3B42.SGD","LU1435385759.SGD","IE00BLSP4239.USD","LU0323591593.USD","BK4534"],"gpt_icon":1},{"id":"2518228165","title":"Icotrokinra Meets Primary Endpoint of Clinical Response in Ulcerative Colitis Study and Shows Potential to Transform the Treatment Paradigm for Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2518228165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518228165?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:00","pubTimestamp":1741608019,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT10C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2129689605.HKD","IE0009355771.USD","LU2592432038.USD","LU0345770993.USD","LU0234570918.USD","SG9999002232.USD","LU2347655156.SGD","LU1935042991.SGD","LU1059921491.USD","BK4532","LU1894683264.USD","LU1221951129.SGD","IE00BGHQF631.EUR","LU1074936037.SGD","IE00B1BXHZ80.USD","LU0289739699.SGD","LU0345770308.USD","BK4559","IE00B2B36J28.USD","BK4007","LU1244550494.USD","LU0320765646.SGD","LU0345769631.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU1778281490.HKD","LU0058720904.USD","IE00BVYPNW00.USD","LU2089984988.USD","LU1914381329.SGD","LU0882574055.USD","SG9999002224.SGD","LU1066051225.USD","BK4534","LU0203347892.USD","BK4585","IE00B3PB1722.GBP","IE00B42XCP33.USD","LU1066051811.HKD","LU2129689514.USD","LU2430703095.HKD","LU2602419157.SGD","LU2430703178.SGD","LU1674673691.USD","LU1261432733.SGD","LU1280957306.USD","LU2133065610.SGD","JNJ","LU1221951046.USD","LU0345769128.USD"],"gpt_icon":0},{"id":"2518228141","title":"J&J: Icotrokinra Was Well Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2518228141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518228141?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:00","pubTimestamp":1741608019,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT10C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2089984988.USD","LU1221951046.USD","IE00B42XCP33.USD","LU0345769128.USD","LU2592432038.USD","BK4534","IE00B2B36J28.USD","LU1066051225.USD","LU0203347892.USD","LU0234570918.USD","BK4007","SG9999002232.USD","LU1280957306.USD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU1059921491.USD","LU1221951129.SGD","LU2133065610.SGD","LU2430703178.SGD","LU2430703095.HKD","IE00B1BXHZ80.USD","BK4559","LU1066051811.HKD","SG9999002224.SGD","LU1023059063.AUD","BK4532","BK4585","IE00BGHQF631.EUR","LU0345769631.USD","LU1261432733.SGD","LU0058720904.USD","LU1778281490.HKD","LU1244550494.USD","LU2129689605.HKD","IE0009355771.USD","LU1674673691.USD","LU2347655156.SGD","LU0320765646.SGD","LU1935042991.SGD","IE00B3PB1722.GBP","LU0345770993.USD","LU2602419157.SGD","IE00BVYPNW00.USD","LU0289739699.SGD","LU1914381329.SGD","LU1894683264.USD","LU1074936037.SGD","LU0345770308.USD","JNJ","LU2129689514.USD"],"gpt_icon":0},{"id":"2518229575","title":"Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2518229575","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518229575?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:00","pubTimestamp":1741608000,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., March 10, 2025----Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the initiation of MOMENTUM, a clinical trial examining the prevalence of endogenous hypercortisolism  in patients with resistant hypertension.The MOMENTUM trial, which will enroll 1,000 patients across 45 sites in the U.S., will establish the prevalence of endogenous hypercortisolism in patients with resistant hypertension. Resistant hypertension is defined by the American Heart Association as elevated blood pressure despite the use of three or more antihypertensive medications in different classes, including a diuretic. Patients with a dexamethasone suppression test  value greater than 1.8 g/dL and dexamethasone levels greater than 140 ng/dL will be identified as having hypercortisolism","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-therapeutics-initiates-momentum-trial-120000275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CORT","BK4532","BK4007","LU0566484027.USD","LU1559883803.SGD","DST"],"gpt_icon":0},{"id":"2518223792","title":"Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2518223792","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518223792?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:00","pubTimestamp":1741608000,"startTime":"0","endTime":"0","summary":"Clinical response and remission rates continued to improve through Week 28, building on strong data recently reported for the plaque psoriasis Phase 3 program. Icotrokinra demonstrates potential to offer therapeutic benefit and tolerability with a once daily oral treatment. SPRING HOUSE, Pa., March 10, 2025 /PRNewswire/ -- Johnson & Johnson today announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra , the first investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis . The study met its primary endpoint of clinical responsea in all icotrokinra dose groups evaluated and demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remissionb, symptomatic remission and endoscopic improvement at Week 12.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/icotrokinra-meets-primary-endpoint-clinical-120000377.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/icotrokinra-meets-primary-endpoint-clinical-120000377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1032466523.USD","LU2505996681.GBP","LU1221951046.USD","IE00B19Z3B42.SGD","LU2468319806.SGD","BK4534","LU1718418525.SGD","LU0640476718.USD","IE0034235303.USD","LU1061106388.HKD","LU1280957306.USD","IE00B4R5TH58.HKD","LU1506573853.SGD","IE00BJJMRZ35.SGD","LU0098860793.USD","LU1221951129.SGD","LU2133065610.SGD","LU2430703178.SGD","LU2430703095.HKD","IE0002141913.USD","LU2430703251.USD","BK4559","LU1674673428.USD","LU1430594728.SGD","LU0122379950.USD","BK4532","LU0345769631.USD","LU1196500208.SGD","LU1261432733.SGD","LU1778281490.HKD","LU0792757196.USD","LU1244550494.USD","IE0009355771.USD","LU1674673691.USD","LU2347655156.SGD","LU0320765646.SGD","BK4568","LU1935042991.SGD","LU0345770993.USD","IE00B7SZLL34.SGD","IE00BVYPNW00.USD","LU0289739699.SGD","LU1914381329.SGD","LU1162221912.USD","BK4504","LU0345770308.USD","LU0203345920.USD","JNJ","LU1244550577.SGD","IE000M9KFDE8.USD"],"gpt_icon":0},{"id":"2518223381","title":"4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2518223381","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518223381?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:00","pubTimestamp":1741608000,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., March  10, 2025  (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targete","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039669/0/en/4DMT-Announces-First-Patients-Enrolled-in-4FRONT-1-Phase-3-Clinical-Trial-Evaluating-4D-150-in-Wet-AMD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109392836.USD","IE00BMPRXN33.USD","BK4614","IE0009356076.USD","LU0719512351.SGD","LU0390134368.USD","LU1988902786.USD","GFS","LU2264538146.SGD","LU1880398554.USD","BK4534","LU2360106780.USD","BK4588","LU2098885051.SGD","LU0979878070.USD","LU0823421333.USD","LU1803068979.SGD","BK4605","BK4566","LU0823421416.USD","LU1242518931.SGD","LU1880398471.USD","LU1923623000.USD","BK4532","BK4575","LU1989764664.SGD","LU2250418816.HKD","LU2458330243.SGD","BK4554","BK4585","IE00BMPRXR70.SGD","LU0081259029.USD","LU0889565833.HKD","LU1242518857.USD","LU0056508442.USD","LU1852331112.SGD","IE0004445239.USD","LU1303367103.USD","LU1316542783.SGD","BK4573","LU2458330169.SGD","BK4512","LU2054465674.USD","LU0082616367.USD","BK4529","LU0642271901.SGD","BK4612","IE00B5949003.HKD","BK4141"],"gpt_icon":1},{"id":"2518805228","title":"US STOCKS-Futures decline as tariff concerns persist; Tesla falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2518805228","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518805228?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:57","pubTimestamp":1741607839,"startTime":"0","endTime":"0","summary":"US STOCKS-Futures decline as tariff concerns persist; Tesla fallsFor a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news windowUS-listed shares of Chinese companies drop after weak economic dataCrypto stocks fall on lower bitcoin pricesAirbnb climbs on bullish brokerage ratingFutures off: Dow 0.91%, S&P 500 1.06%, Nasdaq 1.21%Updates with analyst commentBy Johann M Cherian and Pranav Kashyap","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL4N3PT0QR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLA","LU0561508036.HKD","HBBD.SI","USAW.SI","LU1642822529.SGD","NVDS","HK0000306685.HKD","NVDU","ABNB","3NVD.UK","LU2552382132.HKD","NVDS.UK","LU0052750758.USD","LU2458330243.SGD","LU2065171402.SGD","SNVD.UK","LU1188198961.HKD","LU0048597586.USD","BK1502","LU1699723380.USD","NVD","LU1880383440.USD","LU0823413660.USD","EVS.SI","NVD3.UK","NVDD","NVDY","NVIW.SI","NVD2.UK","2NVD.UK","TSYW.SI","STRK","89988","BK4579","BK4532","SG9999001069.SGD","SG9999000418.SGD"],"gpt_icon":1},{"id":"2518409192","title":"Novo Nordisk's CagriSema Meets Primary Endpoint in Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2518409192","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518409192?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:43","pubTimestamp":1741607039,"startTime":"0","endTime":"0","summary":"Novo Nordisk  said Monday that its phase 3 trial evaluating CagriSema -- a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg --met its primary endpoint in 1,206 overweight or obese patients with type 2 diabetes.The trial showed a \"statistically significant and superior weight loss\" with CagriSema compared to placebo at week 68. Patients on CagriSema achieved a 15.7% weight loss, versus 3.1% in the placebo group, the company said.Additionally, 89.7% of CagriSema-treated patients achieved at least 5% weight loss, which was a co-primary endpoint, compared with 30.3% with placebo.Novo Nordisk said CagriSema was well-tolerated, with mostly mild to moderate gastrointestinal side effects.The company plans to seek regulatory approval in Q1 2026.Novo Nordisk shares were down more than 5% in recent premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BKVL7J92.USD","NVO","BK4599","BK4007","LU1093756325.SGD","BK4585","BK4588","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4532","LU1093756168.USD","NVO.AU","BK7104"],"gpt_icon":1},{"id":"2518225699","title":"Nio Making Organizational Changes To Focus More On Cost Control, Report Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2518225699","media":"CnEVPost","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518225699?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:43","pubTimestamp":1741607026,"startTime":"0","endTime":"0","summary":"Nio has introduced a CBU system to strengthen cost control, and multiple functions will be downsized based on full-year targets, according to local media.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cnevpost.com/2025/03/10/nio-organizational-changes-cost-control-report/","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Nio Making Organizational Changes To Focus More On Cost Control, Report Says","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cnevpost_highlight","symbols":["BK4531","BK4532","BK4581","LU0052750758.USD","BK4555","BK4574","NIO","BK4588","BK4509","LU0708995583.HKD","BK4504","09866","BK4099","BK4505","BK4534","EVS.SI","BK4585","NIO.SI","LU0320764599.SGD","BK4526","BK4548"],"gpt_icon":1},{"id":"2518624038","title":"Incyte (INCY) Receives a Hold from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2518624038","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518624038?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:36","pubTimestamp":1741606572,"startTime":"0","endTime":"0","summary":"In a report released today, Stephen Willey from Stifel Nicolaus maintained a Hold rating on Incyte (INCY – Research Report), with a price target of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/incyte-incy-receives-a-hold-from-stifel-nicolaus-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/incyte-incy-receives-a-hold-from-stifel-nicolaus-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BK4588","INCY","BK4127","BK4585","BK4139","BK4532","BK4550"],"gpt_icon":0},{"id":"2518024038","title":"Novo Nordisk down 6% after results for trial of weight-loss drug CagriSema","url":"https://stock-news.laohu8.com/highlight/detail?id=2518024038","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518024038?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:31","pubTimestamp":1741606272,"startTime":"0","endTime":"0","summary":"Shares of Novo Nordisk (NVO) trading in New York are down $5.22, or 6%, to $81.95 in the pre-market session. Published first on TheFly – the ultima...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-down-6-after-results-for-trial-of-weight-loss-drug-cagrisema?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-down-6-after-results-for-trial-of-weight-loss-drug-cagrisema?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0154236417.USD","BK4599","BK4532","BK4588","IE00BKVL7J92.USD","NVO","LU1093756325.SGD","LU1093756168.USD","BK4007","IE00BZ1G4Q59.USD","BK4585"],"gpt_icon":0},{"id":"2518228279","title":"Returns On Capital At Hello Group (NASDAQ:MOMO) Have Hit The Brakes","url":"https://stock-news.laohu8.com/highlight/detail?id=2518228279","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518228279?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:28","pubTimestamp":1741606111,"startTime":"0","endTime":"0","summary":"Did you know there are some financial metrics that can provide clues of a potential multi-bagger?Firstly, we'll want to see a proven return on capital employed  that is increasing, and secondly, an expanding base of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. However, after investigating Hello Group , we don't think it's current trends fit the mold of a multi-bagger.Return On Capital Employed : What Is It?Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income  a company earns on the capital invested in its business. Analysts use this formula to calculate it for Hello Group:. Return on Capital Employed = Earnings Before Interest and Tax  ÷ . In summary, Hello Group isn't reinvesting funds back into the business and returns aren't growing. Since the stock has declined 46% over the last five years, investors may not be too optimistic on this trend improving either. In any","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/returns-capital-hello-group-nasdaq-112831020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKPKM429.USD","BK4531","BK4513","NVIW.SI","MNQmain","BK4588","BK4112","IE00BGHQF748.EUR","USAW.SI","EBIT","BK4508","TQQQ","LU2210149790.SGD","USJW.SI","IE00B64PRP62.GBP","BK4532","BK4502","BK4526","IE00B3QW5Z07.USD","NDAQ","BK4585","TSYW.SI","MOMO","LU2095319765.USD","PSQ","LU2210150020.SGD",".IXIC","NQmain","SQQQ","BK4077","QLD","QID"],"gpt_icon":1},{"id":"2518401102","title":"ServiceNow Close To Buying AI Startup Moveworks In $3 Billion Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2518401102","media":"Blockhead","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518401102?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:25","pubTimestamp":1741605951,"startTime":"0","endTime":"0","summary":"Aiming to speed up its artificial intelligence push, software maker ServiceNow is in talks to acquire AI startup Moveworks for $3 billion, said a report.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2020/04/Stock-ServiceNow-04-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2020/04/Stock-ServiceNow-04-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/servicenow-stock-acquire-ai-startup-moveworks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU1046421795.USD","BK7142","LU0109391861.USD","LU0353189680.USD","LU2756315318.SGD","LU2461242641.AUD","LU1316542783.SGD","LU0943347566.SGD","LU0354030511.USD","BK4550","LU1951200564.SGD","LU0127658192.USD","LU1267930730.SGD","LU2125909593.SGD","LU1989764748.USD","LU1720051108.HKD","BK4567","IE00B19Z9P08.USD","LU0648001328.SGD","LU2264538146.SGD","LU1116320901.HKD","LU0048573561.USD","NOW","CRM","LU2125909759.SGD","LU2125909916.SGD","BK4534","BK4528","LU2361044949.HKD","IE00B19Z9Z06.USD","LU1988902786.USD","LU0672654240.SGD","CRM.AU","BK4532","LU1803068979.SGD","LU0557290698.USD","LU2361044865.SGD","LU2361045086.USD","LU2125909247.SGD","IE00BKVL7J92.USD","LU1116320737.USD","LU0124676726.USD","LU1496350171.SGD","LU1989772923.USD","LU1804176565.USD","LU2265009873.SGD","LU0820561818.USD","LU1989764664.SGD","LU2458330243.SGD","LU1923623000.USD"],"gpt_icon":0},{"id":"2518421262","title":"Egg prices have become a symbol of our economic fragility","url":"https://stock-news.laohu8.com/highlight/detail?id=2518421262","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518421262?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:21","pubTimestamp":1741605660,"startTime":"0","endTime":"0","summary":"Why are eggs so important in our battle against inflation?The Justice Department has launched an investigation into the reasons for the surge in egg prices, the Wall Street Journal reported Friday, citing people familiar with the issue. Antitrust enforcers will focus on whether producers have conspired to hike egg prices.The price of eggs has risen by 50% over the past year. The average cost of a dozen Grade A large eggs hovers at $4.95, up 240% from $1.46 five years ago. We grudgingly accept those kinds of price hikes with real estate, especially if we are homeowners. But eggs?Eggs are an \"inelastic\" commodity: as prices rise customers don't necessarily stop buying them; there are precious few alternatives. Economist Jason Lusk says a 1% rise in price only reduces demand by 0.15% and, if the supply falls by 1%, prices will rise by about 6.67%.The Trump administration last month announced a $1 billion plan to combat avian influenza, to protect the U.S. poultry industry and - in theory,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","LU1069344957.HKD","LU1116320737.USD","BK4533","LU1551013342.USD","BK4610","LU1201861249.SGD","LU0312595415.SGD","LU1066053197.SGD","VITL","LU0820561909.HKD","LU1551013425.SGD","LU2360032135.SGD","LU0882574139.USD","LU2125154778.USD","LU0417517546.SGD","BK4559","IE00BKVL7J92.USD","LU0265550359.USD","SBUX","BK4212","BK4532","LU0471298694.HKD","BK4596","LU0265550946.USD","BK4504","LU1496350502.SGD","LU0385154629.USD","IE0008368304.USD","LU2210149790.SGD","LU0823411888.USD","LU2360106947.USD","BK4550","BK4209","LU0130102774.USD","BK4535","LU1323610961.USD","LU0302445910.USD","LU0980610538.SGD","LU2125154935.USD","KR","LU0471298777.SGD","LU1035775433.USD","LU0256863811.USD","LU0079474960.USD","LU0234570918.USD","LU1066051498.USD","BK4588","CALM"],"gpt_icon":1},{"id":"2518221251","title":"Can EL Stock Bounce Back in Fiscal 2025 Amid Challenges?","url":"https://stock-news.laohu8.com/highlight/detail?id=2518221251","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518221251?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:13","pubTimestamp":1741605180,"startTime":"0","endTime":"0","summary":"The Estee Lauder Companies Inc. EL is focused on transforming its business through the expanded Profit Recovery and Growth Plan . Its \"Beauty Reimagined\" vision aims to broaden consumer reach, drive innovation and increase investments in digital channels. However, challenges remain, particularly with weak performance in key markets such as China and pressure on its travel retail sector.Let’s explore how The Estee Lauder Companies plans to navigate these challenges and drive future growth.Despite these positive developments, The Estee Lauder Companies is battling a challenging environment marked by weaknesses across China and travel retail. These factors put pressure on its seco","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/el-stock-bounce-back-fiscal-111300567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NUS","LU2552382215.SGD","BK4588","LU2552382058.USD","EL","BK4533","BK4183","LU0690374961.EUR","LU2552382132.HKD","BK4548","LU0266013472.USD","BK4558","URBN","BK4532","BK4146","BK4504","LU2404859667.USD","BK4567","LU2404859741.USD","BK4585","LU0690374615.EUR","BK4094","DECK"],"gpt_icon":0},{"id":"2518524492","title":"Jazz Pharmaceuticals Plc : H.c. Wainwright Raises Target Price to $217 From $200","url":"https://stock-news.laohu8.com/highlight/detail?id=2518524492","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518524492?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:09","pubTimestamp":1741604972,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nAZN3J7WT3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","BK4533","LU0320765992.SGD","BK4007","LU0889565916.HKD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","JAZZ","LU0823416689.USD","IE00BN0W2W23.USD","LU0109394709.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":103,"pageCount":28,"totalSize":1643}]}}